Moleculin Biotech, Inc. Stock price
Is Moleculin Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.
Key metrics
Moleculin Biotech, Inc. Stock Analysis
Analyst Opinions
9 Analysts have issued a Moleculin Biotech, Inc. forecast:
Analyst Opinions
9 Analysts have issued a Moleculin Biotech, Inc. forecast:
Don't miss a Thing! We will send you all news about Moleculin Biotech, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Moleculin Biotech, Inc. Stock News
Company Profile
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
| Head office | United States |
| CEO | Mr. Klemp |
| Employees | 17 |
| Founded | 2015 |
| Website | moleculin.com |


